AJP - Endo Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 285: E899-E905, 2003. First published July 1, 2003; doi:10.1152/ajpendo.00036.2003
0193-1849/03 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
285/4/E899    most recent
00036.2003v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yarasheski, K. E.
Right arrow Articles by Semenkovich, C. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yarasheski, K. E.
Right arrow Articles by Semenkovich, C. F.

TRANSLATIONAL PHYSIOLOGY

Visceral adiposity, C-peptide levels, and low lipase activities predict HIV-dyslipidemia

Kevin E. Yarasheski, Pablo Tebas, Sherry Claxton, Donna Marin, Trey Coleman, William G. Powderly, and Clay F. Semenkovich

Division of Endocrinology, Metabolism and Lipid Research, Division of Infectious Diseases, Departments of Internal Medicine, Cell Biology and Physiology, Washington University Medical School, St. Louis, Missouri 63110

Submitted 24 January 2003 ; accepted in final form 24 June 2003

Protease inhibitor-based highly active antiretroviral therapy (PI-HAART) has been implicated in dyslipidemia, peripheral insulin resistance, and abnormal adipose tissue deposition in human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome, or AIDS. In vitro evidence indicates that some PIs reduce adipocyte lipoprotein (LPL) and hepatic lipase (HL) expression and activities. We examined whether LPL and HL activities are reduced in HIV-infected patients with dyslipidemia. Fasting serum lipids, glucoregulatory hormones, and postheparin LPL and HL activities, as well as whole body and regional adiposity, were measured in 19 HIV-seronegative controls, 9 HIV+ patients naive to all anti-HIV medications, 9 HIV+ patients naive to PIs, 9 HIV+ patients with prior PI experience but not currently receiving PIs, and 47 HIV+ patients receiving PI-HAART. The PI-HAART group had low LPL and HL activities. However, multiple linear regression analysis indicated that low postheparin LPL activity contributed only partially to HIV-dyslipidemia. Central adiposity and high C-peptide levels (an indicator of high insulin secretion) were stronger predictors of HIV-dyslipidemia. Low LPL and HL activities, by themselves, were insufficient to explain HIV-dyslipidemia because the PI-naive group had low LPL and HL activities but had normal adiposity, C-peptide levels, and serum lipid and lipoprotein levels. HDL-cholesterol was lower in PI-HAART and PI-naive groups than seronegative controls and was directly associated with LPL activity. These findings suggest that HIV-dyslipidemia is mediated primarily by factors that influence triglyceride and lipoprotein synthesis (e.g., central adiposity and hyperinsulinemia) and mediated only partially by factors that influence triglyceride clearance (e.g., lipase activity).

acquired immunodeficiency syndrome; human immunodeficiency virus; metabolic complications; insulin resistance; central obesity; aspartyl protease inhibitors; lipoprotein lipase; magnetic resonance imaging



Address for reprint requests and other correspondence: K. E. Yarasheski, Washington Univ. Medical School, Division of Endocrinology, Metabolism and Lipid Research, 660 South Euclid Ave., Box 8127, St. Louis, MO 63110 (E-mail: key{at}im.wustl.edu).




This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
W. T. Cade, D. N. Reeds, B. Mittendorfer, B. W. Patterson, W. G. Powderly, S. Klein, and K. E. Yarasheski
Blunted lipolysis and fatty acid oxidation during moderate exercise in HIV-infected subjects taking HAART
Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E812 - E819.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
D. N. Reeds, W. T. Cade, B. W. Patterson, W. G. Powderly, S. Klein, and K. E. Yarasheski
Whole-Body Proteolysis Rate Is Elevated in HIV-Associated Insulin Resistance.
Diabetes, October 1, 2006; 55(10): 2849 - 2855.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2003 by the American Physiological Society.